Menu
Search
|

Menu

Close
X

Idera Pharmaceuticals Inc IDRA.OQ (NASDAQ Stock Exchange Capital Market)

0.99 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 0.99
Open --
Volume --
3m Avg Volume 295,707
Today’s High --
Today’s Low --
52 Week High 2.87
52 Week Low 0.96
Shares Outstanding (mil) 149.63
Market Capitalization (mil) 363.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
16
FY15
0
EPS (USD)
FY18
-0.101
FY17
-0.424
FY16
-0.318
FY15
-0.424
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
22.49
5.73
Price to Book (MRQ)
vs sector
4.86
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.48
16.72
LT Debt to Equity (MRQ)
vs sector
0.07
12.39
Return on Investment (TTM)
vs sector
-70.35
14.61
Return on Equity (TTM)
vs sector
-71.53
16.34

EXECUTIVE LEADERSHIP

James Geraghty
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Vincent Milano
President, Chief Executive Officer, Director, Since 2014
Salary: $50,000.00
Bonus: --
Louis Arcudi
Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary, Since 2011
Salary: $327,600.00
Bonus: $98,300.00
Robert Fletcher
Senior Vice President - Business Development and Strategic Planning, Since 2015
Salary: --
Bonus: --
Joanna Horobin
Senior Vice President, Chief Medical Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

167 Sidney St
CAMBRIDGE   MA   02139-4237

Phone: +1617.6795500

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

SPONSORED STORIES